{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:29:18Z","timestamp":1793651358812,"version":"4.5.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.numecd.2026.104859","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:53:17Z","timestamp":1783407197000},"page":"104859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"36","author":[{"given":"Xiao-Yu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Zhe","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9564-0961","authenticated-orcid":false,"given":"Fang-Yuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.numecd.2026.104859_bib1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"32","author":"Chong","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.numecd.2026.104859_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.038899","article-title":"Burden of coronary artery disease as a predictor of new vascular events and mortality in patients with ischemic stroke: insights from the Norwegian stroke in the young study","author":"Jibril","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.numecd.2026.104859_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.numecd.2026.104859_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083850","article-title":"Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches","volume":"22","author":"Medina-Leyte","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.numecd.2026.104859_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s13679-023-00510-7","article-title":"Obesity and peripheral artery disease: current evidence and controversies","volume":"12","author":"Lempesis","year":"2023","journal-title":"Curr Obes Rep"},{"issue":"11","key":"10.1016\/j.numecd.2026.104859_bib6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s11886-024-02129-z","article-title":"The role of obesity as a cardiac disease risk factor in patients with type 2 diabetes","volume":"26","author":"Koirala","year":"2024","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib7","article-title":"The correlation between the atherogenic index of plasma and the severity of coronary artery disease in acute myocardial infarction patients under different glucose metabolic states","volume":"15","author":"Jin","year":"2025","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.numecd.2026.104859_bib8","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: the advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.numecd.2026.104859_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102403","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients","volume":"49","author":"Singh","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"7","key":"10.1016\/j.numecd.2026.104859_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15070434","article-title":"Metabolomic alterations in patients with obesity and the impact of metabolic bariatric surgery: insights for future research","volume":"15","author":"Anastasiou","year":"2025","journal-title":"Metabolites"},{"issue":"13","key":"10.1016\/j.numecd.2026.104859_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMcp2000280","article-title":"Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes","volume":"384","author":"Kalyani","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.numecd.2026.104859_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.numecd.2026.104859_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104859_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/dom.70121","article-title":"Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: an updated meta-regression analysis incorporating FLOW and SOUL trials","author":"Hasebe","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.numecd.2026.104859_bib16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ehjcvp\/pvae093","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis","volume":"11","author":"Lin","year":"2025","journal-title":"European Heart Journal-Cardiovascular Pharmacotherapy"},{"key":"10.1016\/j.numecd.2026.104859_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.numecd.2026.104859_bib18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.numecd.2026.104859_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/011871529X421551250801194823","article-title":"Oral semaglutide: a step forward in cardiovascular risk management for type 2 diabetes","volume":"25","author":"Ceron","year":"2025","journal-title":"Cardiovasc Haematol Disord - Drug Targets"},{"key":"10.1016\/j.numecd.2026.104859_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-026-02163-7","article-title":"Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis","author":"Zhou","year":"2026","journal-title":"Diabetology & Metabolic Syndrome"},{"key":"10.1016\/j.numecd.2026.104859_bib21","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.numecd.2026.104859_bib22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2019.11.059","article-title":"Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies","volume":"75","author":"Bonsu","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.numecd.2026.104859_bib23","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.numecd.2026.104859_bib24","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104859_bib25","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"19","key":"10.1016\/j.numecd.2026.104859_bib26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.numecd.2026.104859_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.numecd.2026.104859_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.numecd.2026.104859_bib29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.numecd.2026.104859_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.numecd.2026.104859_bib31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-Week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"10160","key":"10.1016\/j.numecd.2026.104859_bib32","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet (london, england)"},{"issue":"9","key":"10.1016\/j.numecd.2026.104859_bib33","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/dc17-2381","article-title":"A 26-Week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin","volume":"41","author":"Lingvay","year":"2018","journal-title":"Diabetes Care"},{"issue":"10148","key":"10.1016\/j.numecd.2026.104859_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.numecd.2026.104859_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.numecd.2026.104859_bib36","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.numecd.2026.104859_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.numecd.2026.104859_bib38","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.numecd.2026.104859_bib39","first-page":"E20","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial (vol 7, pg 356, 2019)","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.numecd.2026.104859_bib40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"12","key":"10.1016\/j.numecd.2026.104859_bib41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"10.1016\/j.numecd.2026.104859_bib42","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet (london, england)"},{"issue":"10313","key":"10.1016\/j.numecd.2026.104859_bib43","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.numecd.2026.104859_bib44","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/dom.14232","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes Metabol"},{"issue":"10300","key":"10.1016\/j.numecd.2026.104859_bib45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10295","key":"10.1016\/j.numecd.2026.104859_bib46","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.numecd.2026.104859_bib47","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.numecd.2026.104859_bib48","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.numecd.2026.104859_bib49","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.numecd.2026.104859_bib50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.numecd.2026.104859_bib51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.numecd.2026.104859_bib52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.numecd.2026.104859_bib53","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"6","key":"10.1016\/j.numecd.2026.104859_bib55","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat Med"},{"issue":"10402","key":"10.1016\/j.numecd.2026.104859_bib56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.numecd.2026.104859_bib57","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.numecd.2026.104859_bib58","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.numecd.2026.104859_bib59","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.numecd.2026.104859_bib61","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.numecd.2026.104859_bib62","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.numecd.2026.104859_bib63","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.numecd.2026.104859_bib64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.numecd.2026.104859_bib66","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.numecd.2026.104859_bib67","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","volume":"106","author":"Selvarajah","year":"2024","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.numecd.2026.104859_bib68","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/ANNALS-24-03849","article-title":"Comparison of dose escalation versus switching to tirzepatide among people with type 2 diabetes inadequately controlled on lower doses of dulaglutide : a randomized clinical trial","volume":"178","author":"Billings","year":"2025","journal-title":"Ann Intern Med"},{"issue":"10489","key":"10.1016\/j.numecd.2026.104859_bib69","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"LANCET (N AM ED)"},{"issue":"11","key":"10.1016\/j.numecd.2026.104859_bib70","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7326\/M21-0893","article-title":"Sodium\u2013glucose Cotransporter-2 inhibitors versus glucagon-like Peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease","volume":"174","author":"Patorno","year":"2021","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01604-7","article-title":"A dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"10.1016\/j.numecd.2026.104859_bib72","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.numecd.2026.104859_bib73","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib74","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41591-025-04102-x","article-title":"Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice","volume":"32","author":"Kr\u00fcger","year":"2025","journal-title":"Nat Med"},{"issue":"10516","key":"10.1016\/j.numecd.2026.104859_bib75","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.numecd.2026.104859_bib76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-8587(24)00304-8","article-title":"Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial 1c","volume":"13","author":"Davies","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib77","article-title":"Adjuvant treatment with empagliflozin or semaglutide increases endothelial progenitor cells in subjects with well-controlled type 1 diabetes mellitus","volume":"47","author":"Prelo\u017enik","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.numecd.2026.104859_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101884","article-title":"Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia\/reperfusion injury","volume":"86","author":"Yang","year":"2023","journal-title":"Ageing Res Rev"},{"issue":"5","key":"10.1016\/j.numecd.2026.104859_bib79","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0022","article-title":"Inhibition of microRNA-139-5p by glucagon-like peptide-1 ameliorates oxidative stress-induced vascular endothelial cell damage via targeting SOD1\/GCLc","volume":"14","author":"Zhang","year":"2025","journal-title":"Endocrine Connections"},{"key":"10.1016\/j.numecd.2026.104859_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes","volume":"66","author":"Luna-Marco","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.numecd.2026.104859_bib81","article-title":"GLP-1 receptor: a new target for sepsis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib82","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-025-02649-0","article-title":"Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients","volume":"24","author":"Lin","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.numecd.2026.104859_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.numecd.2026.104859_bib84","article-title":"Efficacy and safety of glucagon\u2010like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: an umbrella review and evidence map of randomised controlled trials","author":"Yeo","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"21","key":"10.1016\/j.numecd.2026.104859_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/molecules30214240","article-title":"Protein\u2013ligand interactions in cardiometabolic drug targets: focus on weight loss and cardioprotection","volume":"30","author":"Petsas","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.numecd.2026.104859_bib86","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.938365","article-title":"Editorial: treatment with dual incretin receptor agonists to maintain normal glucose levels may also maintain normal weight and control metabolic dysfunction-associated fatty liver disease (MAFLD)","volume":"28","author":"Ord\u00f3\u00f1ez-V\u00e1zquez","year":"2022","journal-title":"Med Sci Monit"},{"issue":"17","key":"10.1016\/j.numecd.2026.104859_bib87","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.numecd.2026.104859_bib88","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326003212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326003212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:57:44Z","timestamp":1793649464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326003212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":86,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0939475326003212"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104859","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104859"}}